(Reuters) -AbbVie on Thursday cut its 2025 adjusted profit forecast as the drugmaker expects to incur $248 million in ...

AbbVie (ABBV) ended the recent trading session at $201.64, demonstrating a -1.73% swing from the preceding day's closing price. This change was narrower than the S&P 500's daily loss of 4.84%. On the ...

In a regulatory filing, AbbVie (ABBV) disclosed that reported GAAP earnings and adjusted non-GAAP earnings for the first quarter of 2025 are ...

Discover whether AbbVie or Sanofi holds the edge in the global immunology market and find out which stock shows more ...

AbbVie is grappling with diminishing Humira sales and is also trading at an above-average P/E. See why I rate ABBV stock as a ...

AbbVie Inc. appeared to find a sympathetic listener as it urged a three-judge panel Wednesday to block a Mississippi statute that requires manufacturers to steeply discount medicines to an unlimited ...

Genmab denies the accusation that it knowingly stole confidential information in a $1.8 billion deal to acquire a cancer drug ...

The general mood among these heavyweight investors is divided, with 43% leaning bullish and 21% bearish. Among these notable ...

Shares of AbbVie Inc. ABBV slid 1.55% to $206.27 Tuesday, on what proved to be an all-around mixed trading session for the ...

Some of the country's largest drugmakers could be impacted by President Donald Trump's reciprocal tariffs, announced on ...

Danish biotech (Nasdaq: GMAB) on Saturday revealed that US pharma major (AbbVie (NYSE: ABBV) has filed a complaint in the US ...